Bacterial diversity in urinary tract infections after urological surgeries

Background and aim Urinary tract infections (UTIs) are complications following urological surgeries, with rates depending on the type of procedure and patient population. Patient outcomes, such as morbidity, hospital stay, and healthcare expenditures, can be greatly affected by UTIs. We aim to investigate the bacterial diversity in UTIs after urological surgeries. Patients and methods From May 2023 through September 2023, 150 patients hospitalized in the Urology Department at Al-Azhar University Hospitals of Assiut for urological surgery were eligible for this prospective study. They had a UTI within 30 days after urological surgery and underwent urine culture and sensitivity. Results There was high sensitivity of isolated organisms to imipenem in 65 (43.33%) patients, to meropenem in 58 (38.67%) patients, to ciprofloxacin in 29 (19.33%) patients, to cefoperazone-sulbactam in 10 (6.67%) patients, to aztreonam in nine (6%) patients, to ceftriaxone in eight (5.33%) patients, to azithromycin in four (2.67) patients, to amoxicillin and clavulanic acid in two (1.33%) patients, to cephalexin in one (0.67%) patient, to vancomycin in one(0.67%) patient, to erythromycin in one (0.67%) patient, to cefepime one (0.67%) in one (0.67%) patient, and to cefotaxime in one (0.67%) patient. Conclusion The isolated organism was Escherichia coli in 100 (66.66%) patients, Klebsiella pneumoniae in 26 (17.2%) patients, Pseudomonas aeruginosa in 12 (8%) patients, Staphylococcus saprophyticus in 10 (6.66%) patients, and Staphylococcus epidermidis in two (1.3%) patients. There was high sensitivity of isolated organisms to imipenem in 98 (65.3%) patients, and there was moderate sensitivity of isolated organisms to cefoperazone-sulbactam in 68 (45.3%) patients, to azithromycin in 68 (45.3%) patients.